BERKELEY, Calif., and VANCOUVER, British Columbia, May 13, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all matters addressed at the annual and special meeting (the “Meeting”) of the holders of common shares of BriaCell held on April 24, 2019.
At the Meeting, shareholders set the number of directors at five and re-elected Jamieson Bondarenko, William Williams, MD, Charles Wiseman, MD, Rebecca Taub, MD, and Vaughn Embro-Pantalony, as directors of the Company for the ensuing year; elected Jamieson Bondarenko as Chairman of the Board; reappointed MNP LLP, Chartered Professional Accountants, as the Company’s auditors for the ensuing year and authorized the directors to fix the auditor’s remuneration. The shareholders also approved ordinary resolutions, without variation, as more particularly described in the accompanying management information circular dated March 22, 2019. The Audit Committee has been appointed as follows: Vaughn Embro-Pantalony and Dr. Rebecca Taub as independent directors and Jamieson Bondarenko as a non-independent director.
“There exists a unique opportunity to advance BriaCell’s remarkable achievements on behalf of breast cancer patients, survivors and deceased, and their families,” remarked Bondarenko, Director and Chairman of the Board. “The complimentary qualities, contacts and skills of BriaCell’s board of directors are exceptional. We’re intensely focused on accelerating development of our immuno-oncology assets while creating shareholder value. The board is fully cognizant of its accountability to shareholders. BriaCell’s board of directors, as disclosed on SEDI.ca, owns 51,374,636 common shares.”
A copy of the Management Information Circular is available under the Company’s profile on SEDAR (www.sedar.com).
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.
BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination Study with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]. The Combination Study is listed in ClinicalTrials.gov as NCT03328026.
BriaCell and Incyte Corporation (NASDAQ: INCY) have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte’s development portfolio with Bria-IMT™ in advanced breast cancer patients.
BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to cover over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.
For additional information on BriaCell, please visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company’s public filings available at www.sedar.com.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
BriaCell Therapeutics Corp.:
Manager, Corporate Development